In life sciences, CMC data holds more power than we realize. When managed strategically, it can accelerate innovation, ensure compliance, and improve decision-making across the product lifecycle. Our latest blog dives into how a master data–led approach can turn complex CMC data into a true business advantage. Read the full blog here https://lnkd.in/geXSS6BT Preeti Irny Desai Colin Wood #LifeSciences #CMC #DataStrategy #PharmaInnovation #MasterData

This week, OneSource holds its annual Customer Advisory Board (CAB) meeting. The meeting kicks off today with a welcome dinner, bringing together partners and colleagues to set the stage for two days of collaboration focused on Advancing Laboratory Performance through Insights, Operational Excellence, and Scientific Services. Over the next two days, OneSource and their clients—representing many of the leading minds and laboratories in global pharma—dive into key topics shaping the future of science and operations: -Quantifying the Business Value of Scientific Services -Environmental, Social & Governance (ESG) -Enabling Compliance and Data Integrity -Vendor Management: Driving Insights, Action, and Accountability -Using AI to Accelerate Data-Informed Decisions To learn more about OneSource’s solutions click here ➡️ https://bit.ly/3IvCf2k

"Digital protocols aren't just more efficient — they're transformational in their power to reshape how trials are executed," said Rob DiCicco, Vice President of Portfolio Management at TransCelerate. At our recent DDF: Mission Possible event in the U.S. and Europe, that transformation was evident as global stakeholders discussed the regulatory readiness, industry adoption, and collaboration reshaping clinical trials into a more digital and connected future. Read: https://lnkd.in/eWj6BnJb  

Every clause counts. Biotech leaders secure better terms by: ✅ Knowing benchmarks ✅ Negotiating scope, timelines, and deliverables ✅ Protecting IP Don’t sign in haste. Build in strategy. #ContractStrategy #BiotechLeadership #ClinicalStartup

Less manual work. More decision-ready insights. 💬 “I’m one of the biggest advocates for Within3… it’s so much less I have to do.” In complex, competitive markets, #pharma success hinges on clarity, speed, and decisive action. Within3 brings together your most critical data sources into one real-time view — so teams can align faster, adapt instantly, and act with confidence. Learn more about turning your data into decision-ready insights: https://hubs.la/Q03KsL8r0 #data #lifesciences #launchexcellence #pharmalaunch #medicalaffairs

$11.7 Billion Acquisition, 1 Critical Data Oversight. A Shaolin Data Science Data Vulnerability Audit exhibit revealed the core threat to a major pharma (NVO): Governance Failure During Scaling. Excluding newly acquired Catalent sites from ICFR is a P1 data risk. It puts the entire manufacturing control at risk. The mandated action is clear: Immediate ICFR Integration. We identify the weakness, then strike with the solution. Is your next big move—M&A, new platform, or expansion—hiding a P1 data vulnerability? Get the Data Vulnerability Audit ($5,000 USD) and get a data-backed diagnostic of your company's exposure. #DataGovernance #MAndA #BigDataAnalytics #ShaolinDataScience

The FDA is setting a new standard for real-world evidence (RWE)—one rooted in transparency, reproducibility, and regulatory-grade rigor. In its new resource, the FDA highlights how RWE has informed approvals, safety communications, and labeling updates over the past decade. This growing reliance on RWE underscores the importance of trustworthy, auditable data that can stand up to regulatory review. At Truveta, we’re proud to deliver regulatory-grade, real-world data that are directly traceable to their source, fully auditable, and trusted by regulators to support high-impact, data-driven decisions. 🔍 Learn more: https://tr.vet/46RhExj

The FDA is setting a new standard for real-world evidence (RWE)—one rooted in transparency, reproducibility, and regulatory-grade rigor. In its new resource, the FDA highlights how RWE has informed approvals, safety communications, and labeling updates over the past decade. This growing reliance on RWE underscores the importance of trustworthy, auditable data that can stand up to regulatory review. At Truveta, we’re proud to deliver regulatory-grade, real-world data that are directly traceable to their source, fully auditable, and trusted by regulators to support high-impact, data-driven decisions. 🔍 Learn more: https://tr.vet/46RhExj

𝗔𝗜 𝗰𝗮𝗻 𝘀𝗶𝗺𝘂𝗹𝗮𝘁𝗲 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻𝘀, 𝗯𝘂𝘁 𝗰𝗮𝗻 𝗶𝘁 𝘀𝗶𝗺𝘂𝗹𝗮𝘁𝗲 𝗰𝗿𝗲𝗱𝗶𝗯𝗶𝗹𝗶𝘁𝘆? Synthetic respondents are reshaping how market research gets done, faster, cheaper, and smarter. But what’s their role - replace or amplify human voices, or speed up iteration processes? Explore our new whitepaper “Synthetic Respondents in Pharma: Opportunity to Fill Gaps, within Guardrails,” authored by Aritra Das, Nishant Agarwal, and Rajan Dua. 🔗Click here to learn more: https://lnkd.in/g-h59Zns #SyntheticRespondents #AIinPharma #DataDrivenInsights #PharmaInnovation #ProcDNA

[𝘾𝘼𝙎𝙀 𝙎𝙏𝙐𝘿𝙔] From Data Overload to Business Strategy: A Biotech Case Study on Actionable Insights Watch this session to see how a leading biotech company used Quillit by Civicom Marketing Research Services to turn data overload into real-time consumer insights for faster decisions. https://lnkd.in/ewbRxpft